New Self-administered Therapy Offers Hope for Myasthenia Gravis patients

Myasthenia gravis, a debilitating autoimmune disorder affecting approximately one in 5,000 individuals, is now benefiting from a groundbreaking new treatment option. This innovative therapy, utilizing a highly selective monoclonal antibody, allows patients to administer the medication themselves via a pre-filled syringe, significantly improving their quality of life.

The disease, characterized by muscle weakness, impacts an estimated 300 people in the Marche region of Italy, with around 100 cases currently managed by the neuromuscular disease center at Macerata hospital. Traditionally, treatment required frequent hospital visits for infusions, frequently enough leading to crowded waiting lists and a substantial disruption to patients’ daily routines.

This new approach involves four-week treatment cycles and is suitable for approximately 80% of patients. by eliminating the need for lengthy hospital infusions, the therapy reduces the burden of managing this chronic condition. Lucia Faretra, a psychologist and myasthenia gravis patient, describes the condition as a “debilitating weakness,” highlighting the profound impact it can have on individuals’ lives.

The advancement of this self-administered therapy represents a significant advancement in the treatment of myasthenia gravis, offering patients greater autonomy and a reduced impact on their overall well-being. Emanuele Medici,Director of Neurology at Macerata Hospital,and Cristina Petrelli,director of the Neurology UOC at Macerata Hospital,have been instrumental in bringing this new treatment option to patients in the region.